Secukinumab induced Behçet's syndrome: a report of two cases.
Journal
Oxford medical case reports
ISSN: 2053-8855
Titre abrégé: Oxf Med Case Reports
Pays: England
ID NLM: 101642070
Informations de publication
Date de publication:
May 2019
May 2019
Historique:
received:
03
10
2018
revised:
20
01
2019
accepted:
07
04
2019
entrez:
15
6
2019
pubmed:
15
6
2019
medline:
15
6
2019
Statut:
epublish
Résumé
Secukinumab is a human monoclonal antibody against IL-17A that has been shown to be effective in psoriasis, psoriatic arthritis and ankylosing spondylitis (AS). On the other hand, in randomized controlled trials among patients with Crohn's disease (CD) and uveitis due to Behçet's syndrome (BS) treated with secukinumab, primary end points were not met and the drug caused more exacerbations compared to placebo. The drug fact sheet states that secukinumab should be used with caution in patients with CD; however, there are no warnings for those with BS. Here, we present two patients with AS treated with secukinumab; we observed exacerbation of BS in one and emergence of
Identifiants
pubmed: 31198577
doi: 10.1093/omcr/omz041
pii: omz041
pmc: PMC6544425
doi:
Types de publication
Case Reports
Langues
eng
Pagination
omz041Références
Gut. 2012 Dec;61(12):1693-700
pubmed: 22595313
Ophthalmology. 2013 Apr;120(4):777-87
pubmed: 23290985
Nat Rev Rheumatol. 2015 Dec;11(12):731-40
pubmed: 26526644
N Engl J Med. 2015 Dec 24;373(26):2534-48
pubmed: 26699169
Ann Rheum Dis. 2017 Jan;76(1):203-207
pubmed: 27169431
Nat Rev Rheumatol. 2018 Feb;14(2):107-119
pubmed: 29296024
J Crohns Colitis. 2018 May 9;:null
pubmed: 29746636
Dis Mon. 2019 Mar;65(3):51-90
pubmed: 30037762